Enzyme-responsive progelator cyclic peptides for minimally invasive delivery to the heart post-myocardial infarction. by Carlini, Andrea S et al.
UC San Diego
UC San Diego Previously Published Works
Title
Enzyme-responsive progelator cyclic peptides for minimally invasive delivery to the heart 
post-myocardial infarction.
Permalink
https://escholarship.org/uc/item/0w4757vx
Journal
Nature communications, 10(1)
ISSN
2041-1723
Authors
Carlini, Andrea S
Gaetani, Roberto
Braden, Rebecca L
et al.
Publication Date
2019-04-15
DOI
10.1038/s41467-019-09587-y
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Enzyme-responsive progelator cyclic peptides
for minimally invasive delivery to the heart
post-myocardial infarction
Andrea S. Carlini1,2, Roberto Gaetani3, Rebecca L. Braden3, Colin Luo3, Karen L. Christman3 &
Nathan C. Gianneschi 2
Injectable biopolymer hydrogels have gained attention for use as scaffolds to promote cardiac
function and prevent negative left ventricular (LV) remodeling post-myocardial infarction
(MI). However, most hydrogels tested in preclinical studies are not candidates for minimally
invasive catheter delivery due to excess material viscosity, rapid gelation times, and/or
concerns regarding hemocompatibility and potential for embolism. We describe a platform
technology for progelator materials formulated as sterically constrained cyclic peptides which
flow freely for low resistance injection, and rapidly assemble into hydrogels when linearized
by disease-associated enzymes. Their utility in vivo is demonstrated by their ability to flow
through a syringe and gel at the site of MI in rat models. Additionally, synthetic functiona-
lization enables these materials to flow through a cardiac injection catheter without clogging,
without compromising hemocompatibility or cytotoxicity. These studies set the stage for the
development of structurally dynamic biomaterials for therapeutic hydrogel delivery to the MI.
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Myocardial infarction (MI) accounts for 46% of all deathsattributed to cardiovascular disease1. Within the firstfew days post MI, an inflammatory response causes
cardiomyocyte death and degradation of the native extracellular
matrix (ECM) by secreted matrix metalloproteinases (MMPs)2.
This in turn can lead to aneurysmal thinning and negative left
ventricular (LV) remodeling within days to weeks. Left untreated,
heart failure results as one of the leading causes of death in the
western world.
Injectable hydrogel-based scaffolds have gained attention as a
therapeutic approach to prevent negative LV remodeling by uti-
lizing materials to stimulate cardiac repair. Materials for this
purpose have included myocardial ECM3, alginate4, and hya-
luronic acid hydrogels5, or employing biomaterials as therapeutic
delivery scaffolds such as naturally derived polymeric hydrogels
(e.g., collagen6, fibrin7, heparin8, and gelatin9), synthetic polymeric
hydrogels (e.g., poly(N-isopropylacrylamide) (PNIPAAm)10,
ureido-pyrimidinone-modified poly(ethylene glycol) (PEG)11,
and chitosan12), and microparticles (e.g., poly (lactic-co-glycolic
acid) (PLGA)13 and dextran14). Despite many successful pre-
clinical studies, wide spread translation and initiation of clinical
trials has been slow, with current studies limited to a myocardial
ECM hydrogel (clinicaltrials.gov identifier NCT02305602) and
alginate (NCT3082508 and NCT01311791). One reason for this
lack of translation is that the majority of these hydrogels are not
candidates for minimally invasive catheter delivery because of
excess material viscosity, their quick gelling nature that can lead
to catheter clogging, and concerns regarding hemocompatibility
since materials can leak into the bloodstream upon injection into
a beating heart15–17. One versatile class of materials that has been
successfully tested in several preclinical MI models using surgical
epicardial injections is self-assembling peptides (SAPs)18–21. SAP
hydrogels are attractive as they: (1) resemble native ECM, (2)
require no additive reagents to induce gelation, (3) are biode-
gradable, (4) are biocompatible, (5) have pore sizes (~5–200 nm)
conducive to promote endothelial cell adhesion and capillary
formation, (6) allow rapid cellular migration because of their
flexibility, (7) are rehealable, (8) do not suffer from batch-to-
batch chemical variability, and (9) are amenable to sequence
modification22,23. However, SAPs have not demonstrated amen-
ability to cardiac catheter delivery.
Previously, we demonstrated that soluble peptide–polymer-
based nanoparticles can aggregate into macromolecular scaffolds
in diseased tissue through the action of endogenously expressed
inflammatory-related enzymes, MMPs, providing a viable method
for targeted accumulation24, prolonged tissue retention25, and
therapeutic delivery26. However, these materials employed a non-
biodegradable functionalized polynorbornene backbone and did
not possess viscoelastic properties. Inspired by recent efforts with
enzyme-responsive peptides27–29 and a study by Nilsson and
coworkers30 utilizing reductively triggered cyclic peptides as
progelators, we focused on developing a cyclic, enzyme-triggered,
responsive peptide platform that would enable minimally invasive
delivery of SAPs to the heart. Specifically, MMP-2/92,31 and
elastase32,33, which are endogenously expressed at the site of MI
during the acute inflammatory (days) and fibrotic (weeks) phases,
provide a useful handle, playing key roles in the healing process
through degradation of ECM and fibrinogen2.
In this work, we engineer cyclic peptide progelators that flow
freely in solution until proteolytically activated (Fig. 1). Model
SAP sequences are prepared as water-soluble, dispersed cyclic
progelators (green rings, Fig. 1a) that contain a substrate recog-
nition sequence for MMP-2/9 and elastase (red) and a handle for
fluorescent labeling. We show that enzymatic cleavage of these
sterically constrained cyclic progelators results in linearization
to generate SAPs (Fig. 1b) which subsequently assemble into
rehealable viscoelastic hydrogels (Fig. 1c). Their low viscosity,
ability to gel at the site of MI, and hemocompatible nature of the
concentrated progelator are demonstrated. In addition, we show
that the progelators are amenable to minimally invasive catheter
injection using an in vitro model system. This opens the possi-
bility of delivering SAPs to the heart via catheter.
Results
Design of responsive SAPs for activatable gelation in vivo.
SAPs undergo spontaneous assembly through electrostatic and
amphiphilic interactions into ordered nanostructures34,35. In
many instances, variation of sequence and charge distribution in
SAPs can influence properties such as secondary structure36, fiber
diameter37, and bulk viscoelasticity38. In our design, we began
with a gellable core based on a model SAP consisting of the repeat
sequence (KLDL)3 (referred to in this study as KLDL), which has
been studied as a non-immunogenic, non-hemolytic, and anti-
microbial scaffold for tissue engineering applications39–41. This
peptide self-assembles spontaneously into β-sheets through
cationic and anionic crosslinking of the Lys and Asp residues and
hydrophobic interactions along the Leu residues. As a proof of
concept for sequence control, we chose to employ an analog of
KLDL hypothesized to alter secondary structural assembly and
achieve modified gel properties. For this purpose, we designed
(KFDF)3 (referred to as KFDF), in which the incorporation of
aromatic Phe residues introduce π–π interactions. From the
KLDL and KFDF SAPs, we engineered a small library of func-
tionalized SAPs and progelators for studying assembly within a
biological relevant environment (Fig. 2 and Supplementary
Figs. 1–3). We first evaluated whether the addition of non-gelling
amino acids from the MMP-2/9 recognition sequence (PLG|LAG)
and cysteine residues used for macrocyclization into the SAP
sequences would interfere with their ability to self-assemble
(Fig. 2a). Predictive computational modeling with open-access
FibPredictor software42 provided initial evidence that functiona-
lized KLDLLinear and KFDFLinear SAPs would experience a switch
in self-assembly orientation from antiparallel to parallel β-sheets.
Regardless, such a design would retain the capacity to form
fibrillar bilayers (Fig. 2b, c and Supplementary Tables 1–2).
Notably in KFDFLinear, Phe residues on each strand are sand-
wiched with analogous residues on neighboring strands, which
facilitate π–π stacking and stronger hydrophobic interactions
than those of Leu-containing peptides. Indeed, with the design
validated in silico, synthetic preparation of the KFDF SAP
resulted in materials with increased mechanical strength without
sacrificing re-healing capacity, inherent to the known KLDL
system43 (Supplementary Fig. 4).
In practice, modified SAPs KLDLLinear and KFDFLinear, retained
the capacity to self-assemble (both experimentally and predicted)
despite modest changes in secondary structure and viscoelastic
properties (Fig. 3). Experimental circular dichroism (CD)
demonstrated that KLDLLinear and KFDFLinear retained β-sheet
conformations (n→ π* transition at 215 nm). However, the
positive peak at ~200 nm (π→ π* transition) found in KLDL and
KFDF is blue-shifted to ~195 nm, indicative of a parallel to
antiparallel orientation switch (Fig. 3a, b)44. Additionally,
KFDFLinear reveals a new high energy minimum at 203 nm
corresponding to π–π* effects resulting from aromatic π–π
interactions in the hydrophobic interior of the bilayer structure
(Fig. 3b)30. This transition is predicted in theoretical spectra from
DichroCalc45 for KFDFLinear (202 nm) and not for KLDLLinear,
which contains no aromatic residues (Fig. 3c, d). Regardless of
altered secondary structure, fiber morphology and bulk viscoe-
lastic properties exhibited minimal changes to that of unmodified
KLDL and KFDF (Fig. 3e–h). Slight drops in storage moduli for
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KLDLLinear and KFDFLinear are attributed to the decreasing molar
concentration of amino acids (hydrogels prepared with respect to
weight at 15 mgmL−1) contributing to β-sheet formation.
Regardless, no significant disruptive effects to gelling capacity,
as defined by tanδ < 1 (Fig. 3g, h) or strain tolerance
(Supplementary Fig. 5), were observed through the introduction
of over 66% more amino acid residues to the SAP sequence. This
exemplifies the robustness of these linear SAPs to sequence
modification and potential capacity to tolerate functional moieties
such as fluorescent tags or small molecule drugs.
a
MMP/elastase 37 °C
β-Sheet fibrilsHydrogelCyclic progelator peptide Self-assembling peptide (SAP)
cb
Fig. 1 Design of cyclic, enzyme-responsive progelator peptides for activatable gelation. a Cyclic progelator peptides, containing gelling sequence (green),
matrix metalloproteinase (MMP)/elastase enzyme cleavage recognition sequence (red), and disulfide bridge (black), resist assembly due to
conformational constraint. Rhodamine-labeled (pink ellipse) self-assembling peptides (SAPs) were employed for in vivo studies as a 5 mol% additive to
provide a means for imaging the hydrogels in ex vivo microscopy analyses. b Enzymatic cleavage results in linearization into SAPs. c SAPs assemble into
viscoelastic hydrogels composed of β-sheets fibrils
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Fig. 2 Sequences and design of self-assembling peptides (SAPs) and cyclic, enzyme-responsive progelators. a Table of SAPs and progelators based on the
(KLDL)3 and (KFDF)3 amino acid gelling sequence with corresponding diagrammatical representations (green is progelator sequence, red is recognition
sequence, pink is fluorophore). Sequences are shown for the base, unmodified SAPs (KLDL and KFDF) and modified SAPs (KLDLLinear and KFDFLinear)
primed for cyclization but lacking fluorescent labels, together with the corresponding cyclized versions (progelators, KLDLCyclic and KFDFCyclic). In addition,
rhodamine-labeled modified SAPs (Rho-KLDLLinear and Rho-KFDFLinear) are shown, together with their corresponding labeled cyclized progelators (Rho-
KLDLCyclic and Rho-KFDFCyclic). The ‘acm' denotes the acetamidomethyl protecting group on Cysteine residues. ‘Rho' designates the 5(6)-
carboxytetramethyl rhodamine label. b, c Modeling predicts β-sheet re-orientation, rather than self-assembly disruption, following significant SAP
functionalization. b Predicted structures and ribbon diagrams (bottom) of KLDL and KLDLLinear SAPs from FibPredictor simulations revealing antiparallel
and parallel β-sheet orientations, respectively. c Predicted structures and ribbon diagrams (bottom) of KFDF and KFDFLinear SAPs from FibPredictor
simulations revealing antiparallel and parallel β-sheet orientations, respectively (see Supplementary Tables 1-2). Ball and stick models of interacting
peptides are displayed with carbon, oxygen, and nitrogen atoms in white, red, and blue, respectively
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Cyclization and progelator formulation. SAP steric constraint
provides a simple and versatile engineering approach for pre-
venting network assembly in a biological environment (Fig. 4).
Functionalized SAP analogs containing an Fmoc protecting group
or rhodamine dye on the N terminus were cyclized through
oxidation of terminal cysteine residues to generate unlabeled and
labeled progelators (Fig. 4a–e). Dilute solution phase macro-
cyclization was complete within 125 min by liquid
chromatography–mass spectrometry (LCMS) (Fig. 4f, h). Com-
bined, matrix-assisted laser desorption/ionization (MALDI),
high‐resolution mass spectrometry (HRMS), and tandem-mass
spectrometry (MS) confirm synthesis of the cyclic products
(Supplementary Fig. 6–8). Ultraviolet (UV) spectra confirm the
presence of rhodamine absorbance in Rho-KLDLCyclic and Rho-
KFDFCyclic progelators (Fig. 4g, i). Pure nonviscous progelators
(Fig. 4j, k) were formulated with a pH switch from basic to
neutral conditions into 1× Dulbecco’s phosphate-buffered saline
(DPBS), pH 7.4 (10 mM peptide) to minimize aggregation, as
determined by light scattering and transmission electron micro-
scopy (TEM; Supplementary Figs. 9–11). Conformational rigidi-
fication via macrocyclization is suspected to induce limited
oligomerization via intermolecular stacking of cyclic constructs
into transient nanotubes (Supplementary Fig. 12), as has been
reported in the literature46,47. Despite this observed secondary
structure, large assemblies were absent by TEM (Supplementary
Fig. 10c). Thus, our formulated cyclic progelators persist as free-
flowing solutions for easy injection in vivo.
Recognition of progelators by inflammatory enzymes. Labeled
cyclic peptide progelators were tested for their responsiveness to
inflammatory-related proteases overexpressed post MI (Fig. 5).
The initial inflammatory response is marked by the recruitment
of abundant neutrophils, which contribute to the release of pro-
teases such as MMPs and elastase in the first days post MI31,48.
The fibrotic phase (weeks post MI) is notable for residually high
MMP concentrations2,31 and elevated sources of elastase from
neutrophil extracellular traps, remaining weeks after neutrophil
apoptosis 32,33.
Rho-KLDLCyclic and Rho-KFDFCyclic were incubated with
MMP-9 catalytic domain and porcine elastase to cleave at
preferential cut sites (Fig. 5a, d). Enzymatic cleavage by active
MMP-9 and elastase (Supplementary Fig. 13) induced visible
aggregation in reaction vials and entangled fibrous meshes by
TEM (Fig. 5b, e), whereas denatured enzymes elicited no
response. At the site of MI, the presence of very high MMP
and elastase concentrations is expected to induce rapid cleavage,
forcing the peptide progelator to assemble and solidify at the
target site. However, other inflammation-associated enzymes or
constitutively expressed extracellular proteases could play a role
in nonspecific degradation. Thus, thermolysin was used to assess
general stability of our material to excess proteolysis and
subsequent hydrogel disassembly in vivo49. Despite the promis-
cuous activity of thermolysin, incubation with Rho-KLDLCyclic
and Rho-KFDFCyclic induced fiber formation by TEM (Fig. 5b, e)
and structural rearrangement by CD (Fig. 5c, f and Supplemen-
tary Fig. 14). Potential intramolecular50 and intermolecular51,52
steric hindrance from these labeled progelators might explain
differences in the CD cleavage kinetics. The similar responsive-
ness of both unlabeled progelators to inflammatory enzymes and
resistance to dissolution by thermolysin demonstrate the
versatility of our general platform for conformational control.
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Fig. 3 Impact of self-assembling peptide (SAP) functionalization on assembly properties. a Experimental circular dichroism (CD) spectra of KLDL (black
dashed line) and KLDLLinear (blue line) SAPs, with labeled minimum at 215 nm (n→ π*). b Experimental CD spectra of KFDF (black dashed line) and
KFDFLinear (blue line) SAPs, with labeled minima at 215 nm (n→ π*) and 203 nm (π→ π*). c Theoretical CD spectra of KLDL (black dashed line) and
KLDLLinear (green line) SAPs from DichroCalc simulations using FibPredictor models. d Theoretical CD spectra of KFDF (black dashed line) and KFDFLinear
(green line) SAPs from DichroCalc simulations using FibPredictor models (see Supplementary Tables 3-4). CD spectra minima denoted with dashed lines.
e Assembled hydrogel photographs and corresponding transmission electron microscopy (TEM) images of the KLDL (left) and KLDLLinear (right) SAPs.
f Assembled hydrogel photographs and corresponding TEM images of the KFDF (left) and KFDFLinear (right) SAPs. Scale bar 50 nm. g Viscoelastic
measurements of storage moduli, G’ (Pa), and damping factor, tanδ, for KLDL (light blue) and KLDLLinear (dark blue). h Viscoelastic measurements of
storage moduli, G’ (Pa), and damping factor, tanδ, for KFDF and KFDFLinear. Gel capacity is defined as tanδ < 1 (dashed line). CD measurements performed
at 500 µM SAP in 10mM Tris buffer, pH 7.4 (n= 3 repeats). SAPs for TEM and rheology/photographs prepared at 100 µM and 15 mgmL−1 in 1×
Dulbecco's phosphate-buffered saline (DPBS; pH 7.4), respectively. Rheological measurements reported for angular frequency of 2.5 rad s−1 (n= 3
repeats). Values are mean ± SEM
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Progelators form viscoelastic and rehealable hydrogels. The
concept behind our cyclic progelator platform relies on upregu-
lated enzymes to initiate assembly and ultimately viscoelastic
gel formation at the site of MI. However, excess proteolysis
in vivo from the ‘soup’ of proteases at the MI may prevent
gelation or retention of hydrogels at the site of injury. To
simulate this environment, we treated our material at 10 mM with
a large quantity of the robust and nonspecific enzyme, thermo-
lysin (Fig. 6). Initially, KLDLCyclic and KFDFCyclic displayed
overlapping storage (G′) and loss (G′′) moduli, indicative of
solutions lacking significant crosslinks or chemical interactions
(Fig. 6a). Incubation with thermolysin initiates rapid gelation as
G′ diverges from G′′. A steady state at 200 min and continuous
measurement of viscoelastic properties revealed no change for up
to 3 days in the presence of thermolysin. Tightly entangled
macromolecular scaffolds are suspected to confer some degree of
resistance to further proteolysis. Furthermore, the resulting gels
displayed rapid healing capacity when subjected to repeat cycles
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Fig. 4 Facile synthesis of sterically constrained and labeled cyclic progelators. a Synthetic scheme for unlabeled (route I) and labeled (route II) KLDLCyclic
and KFDFCyclic progelators. All self-assembling peptides (SAPs) were cyclized under dilute conditions (500 µM) with 5 eq I2 in a mixture of AcOH/MeOH/
H2O to create a soluble progelator. Route I uses N-terminal Fmoc-protected SAPs to improve material separation during chromatographic purification.
Fmoc removal generates the intended unlabeled progelators KLDLCyclic and KFDFCyclic. Route II depicts the synthesis of labeled progelators through N-
terminal modification with 5(6)-carboxytetramethyl rhodamine prior to cyclization. b, c High-performance liquid chromatography (HPLC) (b) monitored at
214 nm and corresponding electrospray ionization (ESI) spectra (c) of Fmoc-KLDLLinear (red), Fmoc-KLDLCyclic (blue), and KLDLCyclic (green) (835.79m/z,
787.76m/z, and 1070.26m/z, respectively) verify purity and mass of synthetic modifications to KLDL peptides. d, e HPLC (d) monitored at 214 nm and
corresponding ESI spectra (e) of Fmoc-KFDFLinear (red), Fmoc-KFDFCyclic (blue), and KFDFCyclic (green) (781.862m/z, 856.17m/z, and 1355.66m/z,
respectively) verify purity and mass of synthetic modifications to KFDF peptides. In both KLDL and KFDF systems, macrocyclization causes a slight
decrease in polarity and Fmoc-deprotection increases progelator polarity. f KLDLLinear SAP macrocyclization kinetics monitored by liquid
chromatography–mass spectrometry (LCMS) at 214 nm reveal complete cyclization after 120min. g Absorbance spectra of unlabeled (black) and labeled
KLDL progelators (pink, λmax= 565 nm for rhodamine signal). h KFDFLinear SAP macrocyclization kinetics monitored by LCMS at 214 nm reveal complete
cyclization after 120min. i Absorbance spectra of unlabeled (black) and labeled KFDF progelators (pink, λmax= 565 nm for rhodamine signal).
j Photographs of KLDLLinear precursor as a hydrogel (left) and the resulting KLDLCyclic progelator as a soluble solution (right). k Photographs of KLDLLinear
precursor as a hydrogel (left) and the resulting KLDLCyclic progelator as a soluble solution (right)
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of excess strain (100%) (Fig. 6b, c). Morphological changes from
rheology samples before and after enzyme incubation are illu-
strated in Fig. 6d, e. Synthetic product analog SAPs in which the
gelator sequence contained flanking substrate residues
(KLDLControl and KFDFControl) were used for simple comparison
with enzyme-induced gelation (Supplementary Figs. 15-16).
Indeed, secondary assembly characteristics (CD), fibril mor-
phology (TEM), and viscoelastic properties (rheology) of
KFDFControl match closely to that of enzymatically cleaved
KFDFCyclic in Fig. 6. We suspect that the slowed kinetics of gel
formation for enzyme-treated KLDLCyclic vs KFDFCyclic is caused
by lower specificity of thermolysin for Leu vs Phe at the P1
position53. With hydrogel assembly following close behind,
increased proteolytic resistance of tightly packed fibers and
limited enzyme diffusion within the porous network54 likely has a
restrictive effect on further progelator linearization and sub-
sequent gel stiffening for all samples. Regardless, thermolysin
cleavage of either progelator generates linear SAPs through the
loss of Leu–Gly–Leu (Supplementary Fig. 17).
To understand the initial stages of self-assembly when
progelators first encounter their target protease in vivo, slow
step-wise cleavage of KFDFCyclic progelator was achieved through
serial additions of dilute thermolysin (Fig. 6f). CD reveals that
linearization by enzyme cleavage causes an increase in peptide
flexibility, shown by a steep decrease in the signal at 204 nm, and
unchanged β-sheet signal from lateral alignment at 215 nm. Tris
(2-carboxyethyl)phosphine (TCEP) was used as a positive control
to represent ideal assemblies of linearized peptides through
b
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complete reduction of the disulfide bond (Fig. 6f and Supple-
mentary Fig. 18). By TEM, reduced peptides assemble as tangled
fibrils, similarly to enzymatically cleaved peptides (Fig. 6g). Thus,
the enzyme-induced gels observed in Fig. 6 are likely forming
through the same self-assembly mechanisms predicted with
KFDFControl. The rheological and spectroscopic results presented
here indicate that our system has potential to tolerate excess
proteolytic degradation in vivo.
Catheter compatibility of cyclic peptide progelators. Minimally
invasive injection of hydrogels into the heart is typically per-
formed through transendocardial injections. Unlike direct epi-
cardial injections performed in small animal models,
transendocardial delivery requires that material should be able to
reside within the catheter for up to hour-long procedures, yet still
flow over multiple injections during this time, and finally only
form a solid gel once it has entered the tissue17,55. Rapid gelation
and/or high viscosity prohibit many injectable hydrogels from
being considered for this minimally invasive delivery route.
KLDLCyclic and KFDFCyclic progelators were amenable to cardiac
catheter injection (Fig. 7). As shown in Fig. 7a, both unmodified
SAPs and cyclic progelators exhibit shear-thinning behavior, but
the viscosities for the latter are over 20× lower for both
KLDLCyclic and KFDFCyclic. Thus, conformational constraint of β-
sheet forming SAPs was sufficient to disrupt favorable unimer
alignment and weakened structural interactions. We reasoned
that SAP cyclization would be sufficient to prevent clogging
during catheter injection (Fig. 7b).
To mimic cardiac catheter injection in vivo, both cyclic
progelators (2 mol% labeled for visualization) were flowed
through the inner nitinol tubing of a 27 G MyoStar transendo-
cardial injection catheter (Fig. 7c). No excess resistance was
detected by manual operation following incubation in the
catheter loop for 60 min for either peptide. Complex viscosity
of cyclic progelators was independent of peptide concentration up
to 10 mM (Supplementary Fig. 19). In contrast, unmodified
KLDL and KFDF SAPs caused immediate catheter clogging.
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Excess resistance from high viscosity and tendency to rapidly
self-assemble during shearing injection could explain why there
are no previous reports of SAPs for cardiac catheter delivery. To
ensure that the shear forces upon cyclic progelators during
injection do not inhibit enzyme activation, peptides were injected
through the catheter into a vial containing thermolysin and
incubated for 3 h (37 °C), resulting in hydrogel formation (Fig. 7e
and Supplementary Movie 1).
Biocompatibility and injection in a rat MI model. In vitro and
in vivo tests were conducted to assess practical application using
SAP cyclic progelators (Fig. 8). Cytotoxicity of both progelators
(KLDLCyclic and KFDFCyclic) and linear SAPs (KLDLLinear and
KFDFLinear) were studied with human cardiac progenitor cells
(CPCs) (Fig. 8a, b). Exposure at high concentration (10 mM) for
4 h showed no difference in toxicity for all peptides (Fig. 8a).
Exposure at 24 and 48 h showed an increase in metabolic activity
for all peptides at each concentration and timepoint comparable
to growth media only (Fig. 8b). This suggests that our various
peptide modifications were not only cytocompatible but also did
not influence cell metabolism and proliferation. We next exam-
ined the KFDFCyclic progelator in hemocompatibility studies and
assessed in vivo gelation (Fig. 8c–i). Biomaterial leakage is a
concern with transendocardial injection since injections are
performed into a beating heart56. Therefore, we assessed hemo-
compatibility of the cyclic progelator to ensure that modification
and cyclization of the SAPs would not generate a thrombogenic
response. Whole human blood clotting times, hemostasis kinetics,
red blood cell (RBC) hemolysis, and pro-thrombotic profiles were
evaluated in the presence of increasing cyclic peptide progelator
concentrations in blood. Activated clotting times (ACT) were
used as a standard method57 that encompasses intrinsic and
common coagulation pathways to assess thrombogenicity. Fur-
thermore, as this method is influenced by increased sample
viscosity due to clot formation, potential peptide cleavage by
blood proteases and resulting self-assembly would decrease clot-
ting times. No adverse effects were observed for up to 1:10 pep-
tide/blood concentrations (Fig. 8c and Supplementary Table 5).
In contrast, collagen showed a significant clot time reduction, and
chelation of calcium prevented clotting altogether. Whole blood
clotting kinetics were also measured in the absence of an activator
to monitor the influence of progelator on hemostasis. Similarly,
no statistical difference in clotting was observed between the
vehicle and the highest progelator concentration (1:10) at any
timepoint (Fig. 8d and Supplementary Fig. 21). In contrast, col-
lagen and glass controls increased the clot rate.
RBC hemolysis in the presence of progelator was used to assess
acute toxicity (Fig. 8e and Supplementary Table 6). Doses up to
1:10 revealed <5% hemolysis, which is below the limit for
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consideration as a hemolytic biomaterial58. Finally, a pro-
thrombotic assay using platelet-poor plasma (PPP) was used to
monitor non-platelet and phospholipid-specific effects on blood
(Fig. 8f), such as potential to inhibit thrombin activity, prevent
crosslinking of fibrinogen, or sequestration of calcium for
decreased platelet activation. This assay has the advantage of
monitoring the intrinsic pathway only, which is useful for
studying surface contact activation in blood–biomaterial interac-
tions. No changes to coagulation rate (slope), half-maximal
coagulation time, and extent of coagulation (Supplementary
Fig. 21) were observed in samples incubated with progelator up to
doses of 1:100 peptide/blood.
With hemocompatibility verified, we applied the progelator in
an initial proof-of-concept study in vivo. Enzyme-responsive
progelator, KFDFCyclic, doped with a small amount of Rho-
KFDFCyclic (5 mol%) for imaging, was injected into the infarct
region 7 days post MI in a rat ischemia–reperfusion model
(Fig. 8g). Assessment of hearts at 24 h post injection confirmed
that progelator effectively gelled at the heart (Supplementary
Figs. 22-23). Histological and fluorescence analysis of heart
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sections revealed hydrogel assembly occurred at the site of MI in
all rats (Fig. 8h, i). No differences were observed in cardiomyocyte
apoptosis or macrophage infiltration (Supplementary Figs. 24-25)
between saline- and peptide-injected infarcts at 24 h post
injection, suggesting that the activation and subsequent gelation
of enzyme-responsive progelators did not increase the infarct
inflammatory response.
Discussion
The number of candidate biomaterials amenable to minimally
invasive cardiac catheter delivery to the heart post MI is limited.
Consequently, translation of promising scaffolds from preclinical
to clinical trials has been rare. In this study, we examined a
platform modification strategy to enable one promising class of
hydrogels, SAPs, to be injectable via a cardiac injection catheter
by conformationally constraining linear SAPs into macrocyclic
progelators which resist self-assembly (Fig. 1). These progelators
were further modified with a substrate recognition sequence for
endogenously expressed MI-associated proteases. We took the
approach of designing peptide sequences based on a known SAP,
and then utilizing in silico modeling to provide preliminary
insight into any modifications that may cause disruption of
gelation (Fig. 2). These modified sequences were then prepared
synthetically for testing. Subsequent experimental analysis of self-
assembly characteristics and mechanical properties agreed well
with these predictions, namely that sequence modifications did
not interfere with self-assembly as β-sheets into fibrils and vis-
coelastic hydrogels (Fig. 3). It is hypothesized that any number of
other SAP sequences used in biomedical applications could
similarly be adapted to our structurally dynamic platform59,60.
The versatility of our platform is demonstrated through the
functionalization of two different SAPs sequences, which exhibit
disparate self-assembly mechanisms, and yet form progelators
with identical responsiveness. Cyclic progelators synthesized in
Fig. 4 lacked the capacity to gel when sterically constrained.
However, they exhibited responsiveness to enzymes that are
inherently active in the MI during both the acute inflammatory
phase and fibrotic phase (Fig. 5). Despite the different cut sites
recognized by MMP-9 catalytic domain, elastase, and thermo-
lysin, similar secondary structure and nanoscale morphology
changes were observed. Bulk cleavage of these sterically con-
strained materials resulted in healable viscoelastic hydrogels that
were stable against excess proteolysis (Fig. 6).
The development of smart structurally dynamic and responsive
materials for tissue engineering post MI is a relatively untapped
field. With many scaffolds, the common issue remains that che-
mical modification (e.g., crosslinks, binding moieties, targeting
motifs, or therapeutics drugs) can negatively impact material
properties such as sample viscosity and gelation kinetics, which
would preclude their use in catheters61. With our design,
mechanical differences (e.g., stiffness or healing kinetics) in the
resulting hydrogel would not affect the initial progelator for-
mulation. Importantly, we provide a demonstration of low-
viscosity peptide-based progelators for use in a cardiac injection
catheter with little resistance to flow (Fig. 7). The results of these
experiments demonstrate that the cyclic progelator acts as a non-
Newtonian fluid for smooth catheter-based injection and still
retains the capacity to solidify when acted upon by endogenously
expressed inflammatory enzymes in the heart, suggesting this
could provide a useful strategy for cardiac catheter delivery
in vivo. While two types of materials have been delivered via
catheter to the heart in clinical trials, namely alginate and a
myocardial ECM hydrogel, our approach could have some unique
advantages since it is a synthetic system that can be precisely
tuned, is well defined, and has limited batch-to-batch variation.
With the potential for tissue leakage into the bloodstream,
thrombogenicity and toxicity of transendocardially injected bio-
materials is a concern. Synthetic modifications to the SAPs were
shown to imbue no cytotoxicity to human CPCs and were
hemocompatible and non-thrombogenic through a comprehen-
sive assessment of whole blood clotting times, hemostatic kinetics,
RBC hemolysis, and pro-thrombotic assays (Fig. 8). A dosing
analysis shows no statistically significant difference in hemostasis
due to increasing progelator concentration in whole blood. The
extent of coagulation in PPP was only altered at the highest
peptide dose which indicates that local high concentrations of
peptide have an minor anti-coagulative effect on the intrinsic
coagulation (contact-based) pathway; furthermore, the impact
that our peptide does have on coagulation was shown to be
independent of platelet-dependent thrombus formation, a key
player in the pathogenesis of acute MI62. This conclusion is
supported by the lack of change in pro-thrombotic profiles when
incubated with collagen, which increases clotting rates only
through the activation of platelet aggregation63. Given a ‘stan-
dard' clinical concentration of 1:10,00056, which assumes that no
material was injected into the heart wall and instead escaped into
the bloodstream, we observed no adverse effects on coagulation at
this clinically relevant dose. These results indicate that this plat-
form for generating an inert cyclic adduct of known SAPs should
not result in unwanted blood interactions during delivery. Our
platform enables facile delivery of a free-flowing progelator, and
on-demand gelation at the site of inflammation (Fig. 8). In vivo
analysis of KFDFCyclic progelator revealed successful gelation of
activated hydrogel scaffolds in a rat MI model, without inducing
an inflammatory response or cardiomyocyte apoptosis. As such,
we have demonstrated a simplistic strategy that uses the naturally
complex MI microenvironment for delivery and smart assembly
in tissue. This proof-of-concept test paves the way for exploring
the amenability of various other SAP systems (e.g., RAD16-II)
with our progelator system for cardiac injection in vivo. Addi-
tionally, there exists the potential to use this platform in con-
junction with various therapeutics. Herein, we observed that
covalent conjugation of a rhodamine dye to cyclic progelators did
not disrupt gelation. We envision a modular system to deliver and
sustain any number of covalently bound therapeutics (e.g., small
molecule drugs or short peptides). For larger therapeutics (e.g.,
cell therapies or growth factors), injecting a mixture with the
cyclic progelators and subsequent encapsulation within locally
activated networks might provide a means for targeted delivery
without the need for complex synthetic chemistries. Ultimately,
our simple strategy for structural control of self-assembling
peptides could be employed for minimally invasive delivery of
promising therapeutic peptides to other forms of injury or disease
where MMPs are upregulated, including osteoarthritis64, cartilage
tissue repair41, nerve damage65, and acute brain injury 66.
Methods
Peptide synthesis. Peptides were synthesized in an AAPPTec Focus XC peptide
synthesizer. Peptides with C-terminal amides were synthesized on rink amide
MBHA resin and peptides with C-terminal carboxylic acids were synthesized on
Wang-OH resin using double coupling conditions for the first amino acid. HBTU
(N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate)
was used as the general coupling agent. When included, 5(6)-carboxytetramethyl
rhodamine was incorporated during the synthesis at the N terminus. General
peptide cleavage and deprotection was performed in 95:2.5:2.5 (%v/v) tri-
fluoroacetic acid (TFA), triisopropyl silane, and H2O, respectively, for 2 h. Cleaved
peptides were precipitated in cold anhydrous ether (3×) to yield solid crude. Semi-
protected peptides containing Cys(acm) were purified prior to cyclization. Fmoc
was temporarily used for unlabeled progelators to improve peak separation during
purification and to monitor cyclization by high-performance liquid chromato-
graphy (HPLC) and electrospray ionization (ESI; Fig. 4b–e). To synthesize cyclic
progelators, iodine was used to simultaneously deprotect Cys(acm) and initiate
disulfide bond formation under dilute conditions to favor intramolecular macro-
cyclization. To a solution of semi-protected peptides (500 µM) in a mixture of
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acetic acid/methanol/H2O (1:16:4) was slowly added 0.1 M methanolic iodide until
the yellow color persisted (~4–5 eq). The reaction was vigorously stirred at room
temperature for 2 h and reaction completion was confirmed by LCMS. After 2 h of
reaction, Amberlite IRA-400 Resin (chloride form) was stirred in the solution for 1
h to quench excess iodine and absorb reacted iodide ions. Filtrated was placed on a
rotary evaporator to remove acetic acid and methanol. The remaining solution was
diluted with H2O and lyophilized to a white powder. By HPLC no dimerization was
observed. For cyclization kinetics analysis (Fig. 4f, h), the N-terminal Fmoc was
temporarily left on unlabeled peptides for improved peak separation during
purification.
Peptide purification and analysis. Analytical scale RP-HPLC analysis of peptides
was performed on a Jupiter Proteo90A Phenomenex column (150 × 4.60 mm)
using a Hitachi-Elite LaChrom L2130 pump with ultraviolet–visible (UV–Vis)
detector (Hitachi-Elite LaChrom L-2420) monitoring at 214 nm, 256 nm, 290 nm,
and 565 nm. Gradients performed over 30 min. LCMS was performed with a
Waters AQUITY UPLC System using a C-18 column over a 4 or 10 min gradient.
Peptides were purified with a Jupiter Proteo90A Phenomenex column (2050 × 25.0
mm) on an Armen Glider CPC preparatory phase HPLC over a 43 min gradient to
yield 90–95% purity. For all RP-HPLC assays and purifications, gradient solvent
systems utilized Buffer A (H2O with 0.1% TFA) and Buffer B (acetonitrile with
0.1% TFA). For all LCMS assays, gradient solvent systems used Buffer A (H2O) and
Buffer B (acetonitrile with 0.1% formic acid). Crude peptide was prepared for
purification in 5:25:70 acetic acid/Buffer A/Buffer B via initial dissolution in acetic
acid with sonication, followed by addition of acetonitrile and then H2O. Unless
otherwise stated, peptides were purified using a gradient of 25–45% Buffer B over
30 min and 50 min for analytical HPLC and preparatory phase HPLC, respectively.
Following purification, product was analyzed by ESI to verify identity (see Sup-
plementary Fig. 3). Due to the large number of cis/trans configurational isomers
that our cyclic progelators could adopt, and amphiphilic self-assembling nature of
our peptides, peak resolution via HPLC was low in many instances. We relied on
various mass spectrometry techniques (ESI, MALDI, HRMS, and tandem-MS) to
verify purity of isolated materials.
UV absorbance spectra. UV absorbance spectra of peptide labeling were mea-
sured on a ThermoScientific Nanodrop 2000c.
Photographs of samples and illustrations. Photographs of vial flips, samples, and
experimental setups were taken with an Android Samsung S7. Adapted clipart
from Servier Medical Art is licensed under a Creative Commons Attribution 3.0
Unported License.
Progelator sterilization and formulation for in vivo analysis. HPLC purified
peptides were dialyzed with 1 kDa molecular weight cutoff tubing into milliQ H2O,
sterile filtered through a 0.2 µm PES filter, and lyophilized to a powder. Peptide was
reconstituted prior to injection with sterile pH 9 H2O to form a clear solution
(11.11 mM), then diluted further with sterile 10× DPBS to a final concentration of
10 mM peptide in 1× DPBS (pH 7.4). Solutions for in vivo analysis contained 5 mol
% rhodamine-labeled progelator (0.5 mM labeled+ 9.5 mM unlabeled) for fluor-
escence imaging purposes.
Transmission electron microscopy. Formvar/Carbon-coated 400 mesh Cu grids
(Ted Paella, Inc.) were glow discharged for 90 s and spotted with 4–5 µL peptide
sample (100 µM) and set for 5 min. Grids were washed with distilled H2O (10
drops), stained with 1% w/w uranyl acetate (3 drops), and wicked dry with filter
paper. TEM images were acquired on an FEI Tecnai G2 Sphera at 200 kV.
Experimental CD. Peptides were dissolved at a final concentration of 125 µM
(labeled peptides) or 500 µM (unlabeled peptides) in 10 mM Tris buffer or H2O
(for TCEP reduction only) at pH 7.4 to reduce signal interference seen with DPBS
at lower wavelengths. UV–Vis CD was measured on a Jasco J-810 Spectro-
polarimeter to evaluate the secondary structure of peptide samples. Measurements
were taken using the following settings: wavelength range= 190–260 nm, scanning
speed= 50 nmmin−1, response time= 2 s, data pitch= 1 nm, band width= 1 nm,
accumulations= 3, pathlength= 1 mm, and temperature= 37 °C. Spectra are
presented as an average of all accumulations. Sample voltage was monitored to
verify the signal intensity did not exceed 800 mV within the wavelength range.
Spectra were converted from units of millidegrees (mdeg) to molar ellipticity [θ]
using the following equation:
θ½  ¼ mdeg M
C  L  10 ; ð1Þ
where mdeg is the measured absorbance of circularly polarized light, C is con-
centration in g L−1, M is the mean residual weight in g mol−1, and L is the cell
pathlength in cm.
Computational modeling with FibPredictor. FibPredictor was utilized as a
commercially available software for generating native-like amyloid fibril
structures42. This software was chosen for our study due to its unique ability to
reliably model all classes of amyloid fibrils starting from sequence-only input. The
algorithm combines β-sheet model building, β-sheet replication, and symmetry
operations with side-chain prediction and statistical scoring functions for com-
putational predictions on amyloid fibril structures of self-assembling peptides
utilized in this study. From each random model generated, a SCRWL internal
scoring function was used by SCWRL4 to predict the energetically lowest side-
chain orientations. This scoring function was used to calculate the minimal total
energy of the entire model and output coordinates for the structure as a PDB file
(see Supplementary Data) with predicted side chains using the same residue
numbering and chain identifiers as the input structure. To identify the most
energetically favorable candidate structures in the ensemble, both Amb_3b (com-
putationally more efficient)67 and GOAP (more accurate)68 statistical scoring
functions were used to calculate total energies of the protein structure. Reported
energies are unitless as they are empirically derived scores, and thus it is not
advisable to interpret results as kcal mol−1. Normalized GOAP scores are useful for
comparing fibrils of different sizes. Three generations of modeling were performed
with literature-recommended parameters shown in Supplementary Table 1. Results
of top model for each peptide sequence from the third-generation analysis are
reported in Supplementary Table 2. Corresponding structures and raw PDB files
are provided in the main text Fig. 2 and as Supplementary Data. Output PDB files,
containing the atomic coordinates of the chromophores, from top models were
used to generate theoretical CD spectra with DichroCalc45.
Theoretical CD spectra with DichroCalc. DichroCalc was used to calculate CD
spectra using predicted PDB from FibPredictor. This web interface predicts sec-
ondary structure type using a variety of matrix method parameters, which have
been derived from ab initio calculations. These parameters include the peptide
chromophore in the far-UV, charge-transfer between neighboring peptide groups
in the deep-UV, and aromatic side-chain chromophores with transitions in the
near-UV. Full analysis CD spectra were output in units of molar ellipticity [θ] vs
wavelength.
In vitro enzyme cleavage of cyclic peptide progelator. Unless otherwise stated,
enzyme cleavage experiments were performed on progelator at a final concentra-
tion of 500 µM in 1× enzyme cleavage buffers. MMP-9 cleavages were performed at
1:1000 enzyme/substrate molar ratio in 1× buffer (50 mM Tris-HCl, 200 mM NaCl,
5 mM CaCl2, 1 mM ZnCl2, pH 7.5) for 5 h. Elastase cleavages were performed at
1:250 enzyme/substrate molar ratio in 1× buffer (100 mM Tris-HCl, 0.2 mM NaN3,
pH 8.0) and thermolysin (50 mM Tris-HCl, 0.5 mM CaCl2) for 5 h. Thermolysin
cleavages were performed at 1:4500 enzyme/substrate molar ratio in 1× buffer (1×
DPBS, pH 7.4) for 15 min. Analysis of unlabeled cyclic peptide progelator cleavage
by CD (Fig. 6f) was conducted with serials additions of thermolysin (4 × 1:18,000
enzyme/substrate) over a period of 73 h in 10 mM Tris buffer. Control samples
utilized denatured enzymes under the same conditions. MMP and elastase were
heat denatured with 10 min of incubation at 65 °C. Thermolysin was inactivated by
incubation with 10% (v/v) EDTA (0.5 M, pH 8.0).
Rheological characterization. All peptide samples were prepared at 10 mM
peptide, except for those used to assess the effect of SAP functionalization with
respect to weight (15 mgmL−1). Viscous and viscoelastic properties were assessed
using a stress-controlled rheometer (TA Instruments AR-G2) equipped with a
Peltier plate to control temperature and a 20 mm diameter parallel plate geometry.
Unless otherwise stated all measurements were taken at an angular frequency of
2.5 rad s−1, strain of 0.5%, and temperature of 37 °C. Measurements were per-
formed with a gap height of 1000 µm and repeated three times (except for step-
strain and time course measurements) to ensure reproducibility. To prevent water
evaporation, mineral oil was wrapped around the edge of the geometry at the
air–sample interface. For viscoelastic measurements the apparatus was used in
oscillatory mode. To ensure the measurements were made in the linear viscoelastic
regime, strain sweeps were performed between 0.05 and 50% strain and showed no
variation in storage (G′) and loss (G″) moduli up to a strain of 0.5%. The dynamic
moduli of the hydrogels were measured as a function of frequency in the range
0.25–100 rad s−1 at a strain of 0.5%. Continuous step-strain oscillations were used
to monitor hydrogel healing through disruption (3 min, 100% strain) and recovery
(15 min, 0.5% strain) cycles (n= 3). For viscosity measurements the apparatus was
used in steady-state flow mode. The viscosity of the samples was measured as a
function of shear rate in the range 0.1–10 s−1 (5% tolerance). For time course
measurements of enzyme activation, a stock of cyclic peptide (1 mL, 10 mM, 1×
DPBS, pH 7.4) was prepared and incubated at 37 °C. A sample from this stock was
applied to the rheometer for storage and loss moduli measurements (2.5 rad s−1,
0.5% strain) over a 35–40 min period. This sample was removed and replaced with
an identical sample mixed via pipetting for 5 s with thermolysin (1:4500 enz/
peptide) followed by immediate addition to the rheometer. Delay time between
enzyme addition and rheology measurements was ~30 s.
In vitro catheter injections and effect on assembly. Peptide solutions (0.6–0.8
mL) were prepared at 10 mM in 1× DPBS (pH 7.4) and loaded into a 1 mL Leur
Lock syringe attached to a syringe pump set to a flow rate of 0.6 mLmin−1. Peptide
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was injected through the 27 G inner nitinol tubing of a MyoStar catheter that was
immersed in a 37 °C water bath.
Hemocompatibility analysis. For all measurements, peptide stocks in 1× DPBS
were prepared such that the final concentrations (v/v) in blood or plasma were
1:10, 1:100, 1:500,1:1000, 1:5000, 1:10,000, and 1:20,000 (peptide/fluid volume).
Controls with collagen as a procoagulant initial platelet-adhesive surface (0.095 mg
mL−1 or 1:240 dilution) or with calcium chelated by sodium citrate utilized 1×
DPBS as a vehicle to ensure consistent blood dilution in all experiments. Peptide
stocks, whole human blood, isolated RBCs, and PPP were warmed to 37 °C
immediately prior to use. Plate reader measurements were conducted on an
EnSpire Multimode Plate Reader with 96-well tissue culture plates (TCP). All blood
studies were done in compliance with the Northwestern University Bloodborne
Pathogens Program. Unspun human whole blood, Na citrate, (BSC, LS 2402453A),
was processed under US FDA registration #2577632 and pre-screened for viral
contaminants (Title 21-CFR PART 610.40).
ACT with whole human blood. A Hemochron 801 instrument calibrated with an
electronic system verification (ESV) device was used to measure ACT of whole
human blood. ACTs were determined using recalcified citrated whole human blood
to minimize variability in starting time points for clotting in all assays. To each
Hemochron P214 tube with glass beads was added 4 µL CaCl2 (1.1 M) and 36 µL
peptide stock or additive (12.2× final blood concentration). Samples were mixed
thoroughly for 30 s to soak the glass beads and incubated for 30 s at 37 °C. Citrated
whole human blood (400 µL) was then added (t= 0 s), mixed by hand for 10 s, and
added to the instrument. Time points at which the magnet was displaced by clot
formation were recorded by the instrument. Collagen (0.095 mgmL−1) was used as
a positive control to decrease clotting time. Vehicle (1× DPBS) served as a standard
for blood without additive. Samples without calcium, serving as the negative
control, exceeded instrument maximum time range (>1500 s). Each experiment
was performed n= 6 times with averages and standard error of the mean (SEM)
plotted.
Whole blood hemostasis kinetics. Changes to time-dependent hemostasis were
monitored using a non-activated whole blood clotting assay. Briefly, 100 µL of
citrated whole human was mixed with 10 µL of peptide or collagen stock (11.5×
final blood concentration) and 5 µL of CaCl2 (230 mM). Collagen (0.095 mgmL−1)
and glass coverslips were used as positive controls to increase clotting rates from an
additive and contact initiated perspective, respectively. Samples without calcium,
where no clot was observed at any timepoint, served as negative controls. Aliquots
(100 µL) were transferred to a 12-well TCP, covered, and incubated at room
temperature for 5, 15, 30, and 45 min. Each sample was prepared in triplicate. At
the end of each timepoint, RBCs not caught in the thrombus were lysed by gently
adding 3 mL distilled H2O and incubating for 5 min. Each well was sampled (200
µL), taking care not to disturb the clot, and transferred to a 96-well plate for
analysis. Released hemoglobin from lysis was detected by measuring the absor-
bance at 405 nm (height 4.0 mm, 100 flashes) using a plate reader. Extent of
clotting is inversely proportional to measured absorbance. Averages (n= 3) and
SEM are plotted.
Hemolysis assay. RBCs were isolated by centrifugation of 40 mL citrated whole
human blood at 500 × g for 5 min, followed by gentle washes with 150 mM NaCl
(×1) and 1× DPBS (×3). Isolated RBCs were diluted 1:50 into 1× DPBS (pH 7.4)
and lightly agitated to prevent settling. Briefly, 190 µL of dilute RBCs and 10 µL of
peptide stock or additive (20× final concentration) were mixed and added to a 96-
well plate (n= 4 repeats), covered, and incubated at 37 °C for 1 h. Plates were
centrifuged at 500 × g to pellet intact RBCs using a centrifuge equipped with a
microplate rotor. Supernatant (100 µL) was transferred to a new 96-well plate,
taking care not to disturb the pellet. Absorbance of the supernatant was measured
at 540 nm to detect released hemoglobin. To calculate % hemolysis, absorbances
were corrected for background absorbance from untreated vehicle and then nor-
malized to 1% Triton X-100-treated RBCs to represent 100% hemolysis. %
Hemolysis was calculated according to the following equation:
%Hemolysis ¼
Absexperiemental
 
 Absnegative control
 
Abspositive control
 
 Absnegative control
  ´ 100; ð2Þ
where Absexperiemental is the average well absorbance pertaining to RBCs pertaining
to the additive sample being analyzed, Absnegative control is the average well absor-
bance for RBCs incubated with vehicle (1× DPBS), and Abspositive control is the
average well absorbance for RBCs containing 1% Triton X-100.
Pro-thrombotic assays. PPP was isolated from citrated whole human blood
through two rounds of centrifugation at 2000 × g for 10 min and collection of the
upper two-third layer. Briefly, 100 µL of PPP, 50 µL of peptide stock or additive (4×
final concentration), and 50 µL of CaCl2 (50 mM) were mixed and added to a 96-
well plate and incubated at 37 °C for kinetics measurements. For each sample, n=
6 repeats were conducted. Coagulation profiles were obtained by measuring well
absorbance at 405 nm at 30 s intervals for 60 min. Onset to clotting was detected as
a sharp increase in sample turbidity.
In vivo studies. All animal experiments were conducted in accordance with the
guidelines established by the Institutional Animal Care and Use Committee at the
University of California, San Diego (UCSD), and the Association for the Assess-
ment and Accreditation of Laboratory Animal Care and approved by the Institu-
tional Animal Care and Use Committee at the UCSD (A3033-01). Female Sprague-
Dawley rats (225–250 g) were used in all studies.
Intramyocardial injections of peptide into infarcted rats. MI was performed via
35 min ischemia–reperfusion and intramyocardial injections were performed under
isoflurane69. Briefly, cyclic peptide (75 µL, 0.75 µmol, 10 mM) was administered as
a single injection into the infarct with a 27 G needle at 7 days post MI. Animals
were euthanized with an overdose of pentobarbital (200 mg kg−1) at 24 h post
injection (n= 5).
Cryosectioning, histology, and immunofluorescence imaging. After euthanasia,
hearts were resected, fresh frozen in TissueTek OCT, and cryosectioned for his-
tological analysis. Slides were either stained with hematoxylin and eosin (H&E) to
identify the infarct region or stained for immunofluorescence analysis. H&E slides
were imaged on an Aperio ScanScope CS2 at ×20 magnification. For immuno-
fluorescence, tissue sections were permeabilized in acetone (−20 °C) for 1.5 min
and blocked with 2% bovine serum albumin and 0.3% Triton X-100 in 1× PBS.
Myocardium was labeled using mouse anti-rat α-actinin antibody (1:800 dilution in
blocking buffer, 1 h of incubation, Sigma A7811) and an Alexa Fluor 488 goat-anti-
mouse IgG secondary antibody (1:500 dilution in blocking buffer, 30 min of
incubation, Thermo Fisher A-11001). Nuclei were labeled using Hoechst 33342
(1:10,000 dilution in deionized water, 10 min of incubation, Life Technologies).
Tissue sections were mounted with Fluoromount (Sigma) and imaged using a Leica
Ariol slide scanner with Ariol software at ×20 magnification.
Human cardiac progenitor cell culture. Human fetal CPCs were isolated from
tissue harvested under standard informed consent procedures and prior approval
of the ethics committee of the University Medical Center Utrecht. All cell studies
were done in compliance with the UC San Diego Human Research Protections
Program. CPCs were isolated from human fetal hearts for selection with Sca-1+
magnetic bead sorting (Miltenyi Biotech, 130-091-176) and cultured on 0.1%
gelatin in growth media. Growth media consists of 25% EGM-2 (Cambrex, CC-
3156) supplemented with EGM-2 Single Quots (Cambrex, CC-4176), 10% fetal
bovine serum, 1× penicillin/streptomycin (Sigma, P4458), and 1× minimum
essential medium (MEM) non-essential amino acids (BioWhittaker, BE13-114E) in
M199 (BioWhittaker, BE12-119F). Cells at passages 3–5 after isolation were tested
for mycoplasma, showing no contamination. Cells at passages 17–21 were used for
all experiments.
Cytotoxicity assays. Material acute cytotoxicity was tested using human CPCs.
The cells were stained with calcein-AM cell viability dye (25 nm; eBioscience) for
30 min and 500,000 cells were resuspended in 50 µL of each peptide (10 mM). After
15 min, 1 mL of growth media was added to the peptide-cell mixture and 50 µL was
transferred into a 24-well plate for imaging. Five to six images were taken per
condition using a fluorescence microscope (Carl Zeiss, Dublin, CA, USA). Cells
resuspended in media only were used as a control. The percentage of viable cells
was determined by counting the stained cells over the total number of cells. Three
experiments were performed (n= 8–12 repeats in duplicate). Alternatively, CPCs
were also cultured up to 4 days with or without peptides, and cytotoxicity was
evaluated by an Alamar blue metabolic activity assay. In all, 3500 hCPCs were
plated into each well of a 96-well plate in growth media. At 24 h after cell seeding,
baseline metabolic activity was taken by incubating the cells in Alamar blue (1:10 in
medium, Invitrogen) for 3 h and analyzing at 550/585 nm with a Synergy™ 4 Multi-
Mode Microplate Reader (Biotek). Peptide was added to cells and cultured for
4 days. Alamar blue assay was repeated after 24 and 96 h, and growth media was
used as control (n= 3 repeats in quadruplicate). Metabolic activity reported as fold
increase vs baseline values.
Statistical analysis. All statistical results are expressed as mean ± SEM. Ordinary
one-way analysis of variance (ANOVA) tests were used for multiple comparisons
of the mean in each group with that of the standard. Tukey's corrections with 95%
confidence intervals and significance were used. Two-way ANOVA tests without
matching were used for multiple comparisons of the mean in each group at each
timepoint with that of the standard. Holm–Sidak test was used for multiple
comparisons. Statistical significance was defined as follows: ns (p > 0.05), *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09587-y
12 NATURE COMMUNICATIONS |         (2019) 10:1735 | https://doi.org/10.1038/s41467-019-09587-y | www.nature.com/naturecommunications
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its Supplementary Information files or from the corresponding authors on
reasonable request.
Received: 23 July 2018 Accepted: 11 March 2019
References
1. Mozaffarian, D. et al. Heart disease and stroke statistics—2016 update.
Circulation 133, 38–360 (2015).
2. Richardson, W. J., Clarke, S. A., Quinn, T. A. & Holmes, J. W. Physiological
implications of myocardial scar structure. Compr. Physiol. 5, 1877–1909
(2015).
3. Singelyn, J. M. et al. Naturally derived myocardial matrix as an injectable
scaffold for cardiac tissue engineering. Biomaterials 30, 5409–5416 (2009).
4. Yu, J. et al. The effect of injected RGD modified alginate on angiogenesis and
left ventricular function in a chronic rat infarct model. Biomaterials 30,
751–756 (2009).
5. Dorsey, S. M. et al. MRI evaluation of injectable hyaluronic acid-based
hydrogel therapy to limit ventricular remodeling after myocardial infarction.
Biomaterials 69, 65–75 (2015).
6. Lee, A. S. et al. Prolonged survival of transplanted stem cells after ischaemic
injury via the slow release of pro-survival peptides from a collagen matrix.
Nat. Biomed. Eng. 2, 104–113 (2018).
7. Losi, P. et al. Tissue response to poly(ether)urethane-polydimethylsiloxane-
fibrin composite scaffolds for controlled delivery of pro-angiogenic growth
factors. Biomaterials 31, 5336–5344 (2010).
8. Prokoph, S. et al. Sustained delivery of SDF-1α from heparin-based hydrogels
to attract circulating pro-angiogenic cells. Biomaterials 33, 4792–4800 (2012).
9. Layman, H. et al. The effect of the controlled release of basic fibroblast growth
factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical
limb ischemic model. Biomaterials 28, 2646–2654 (2007).
10. Fujimoto, K. L. et al. Synthesis, characterization and therapeutic efficacy of a
biodegradable, thermoresponsive hydrogel designed for application in chronic
infarcted myocardium. Biomaterials 30, 4357–4368 (2009).
11. Bastings, M. M. C. et al. A fast pH-switchable and self-healing supramolecular
hydrogel carrier for guided, local catheter injection in the infarcted
myocardium. Adv. Healthc. Mater. 3, 70–78 (2014).
12. Wang, H. et al. Improved myocardial performance in infarcted rat heart by
co-injection of basic fibroblast growth factor with temperature-responsive
Chitosan hydrogel. J. Heart Lung. Transplant. 29, 881–887 (2010).
13. Formiga, F. R. et al. Controlled delivery of fibroblast growth factor-1 and
neuregulin-1 from biodegradable microparticles promotes cardiac repair in a
rat myocardial infarction model through activation of endogenous
regeneration. J. Control. Release 173, 132–139 (2014).
14. Suarez, S. L. et al. Degradable acetalated dextran microparticles for tunable
release of an engineered hepatocyte growth factor fragment. ACS Biomater.
Sci. Eng. 2, 197–204 (2016).
15. Ungerleider, J. L. & Christman, K. L. Concise review: injectable biomaterials
for the treatment of myocardial infarction and peripheral artery disease:
translational challenges and progress. Stem Cells Transl. Med. 3, 1090–1099
(2014).
16. Hernandez, M. J. & Christman, K. L. Designing acellular injectable biomaterial
therapeutics for treating myocardial infarction and peripheral artery disease.
JACC Basic Transl. Sci. 2, 212–226 (2017).
17. Portnov, T., Shulimzon Tiberiu, R. & Zilberman, M. In Rev. Chem. Eng. Vol.
33 91 (2017).
18. Akiyama, N., Yamamoto-Fukuda, T., Takahashi, H. & Koji, T. In situ tissue
engineering with synthetic self-assembling peptide nanofiber scaffolds,
PuraMatrix, for mucosal regeneration in the rat middle-ear. Int. J. Nanomed.
8, 2629–2640 (2013).
19. Davis, M. E. et al. Injectable self-assembling peptide nanofibers create
intramyocardial microenvironments for endothelial cells. Circulation 111,
442–450 (2005).
20. French, K. M., Somasuntharam, I. & Davis, M. E. Self-assembling peptide-
based delivery of therapeutics for myocardial infarction. Adv. Drug Deliv. Rev.
96, 40–53 (2016).
21. Li, X. et al. Image-guided stem cells with functionalized self-assembling
peptide nanofibers for treatment of acute myocardial infarction in a mouse
model. Am. J. Transl. Res. 9, 3723–3731 (2017).
22. Yuan, X., He, B., Lv, Z. & Luo, S. Fabrication of self-assembling peptide
nanofiber hydrogels for myocardial repair. RSC Adv. 4, 53801–53811 (2014).
23. Ravichandran, R., Venugopal, J. R., Sundarrajan, S., Mukherjee, S. &
Ramakrishna, S. Minimally invasive cell-seeded biomaterial systems for
injectable/epicardial implantation in ischemic heart disease. Int. J. Nanomed.
7, 5969–5994 (2012).
24. Chien, M.-P. et al. Enzyme-directed assembly of nanoparticles in
tumors monitored by in vivo whole animal imaging and ex vivo super-
resolution fluorescence imaging. J. Am. Chem. Soc. 135, 18710–18713
(2013).
25. Nguyen, M. M. et al. Enzyme-responsive nanoparticles for targeted
accumulation and prolonged retention in heart tissue after myocardial
infarction. Adv. Mater. 27, 5547–5552 (2015).
26. Callmann, C. E. et al. Therapeutic enzyme-responsive nanoparticles for
targeted delivery and accumulation in tumors. Adv. Mater. 27, 4611–4615
(2015).
27. Kalafatovic, D. et al. MMP-9 triggered micelle-to-fibre transitions for slow
release of doxorubicin. Biomater. Sci. 3, 246–249 (2015).
28. Zhou, J. & Xu, B. Enzyme-instructed self-assembly: a multistep process for
potential cancer therapy. Bioconjug. Chem. 26, 987–999 (2015).
29. Abul-Haija, Y. M. & Ulijn, R. V. In Hydrogels in Cell-Based Therapies 112–134
(The Royal Society of Chemistry, 2014).
30. Bowerman, C. J. & Nilsson, B. L. A reductive trigger for peptide self-assembly
and hydrogelation. J. Am. Chem. Soc. 132, 9526–9527 (2010).
31. Spinale, F. G. Myocardial matrix remodeling and the matrix
metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87,
1285–1342 (2007).
32. Prabhu, S. D. & Frangogiannis, N. G. The biological basis for cardiac repair
after myocardial infarction. Inflamm. Fibros. 119, 91–112 (2016).
33. Vulesevic, B., Sirois, M. G., Allen, B., de Denus, S. & White, M. Subclinical
Inflammation in heart failure: a neutrophil perspective. Can. J. Cardiol. 34,
717–725 (2018).
34. Rad-Malekshahi, M., Lempsink, L., Amidi, M., Hennink, W. E. &
Mastrobattista, E. Biomedical applications of self-assembling peptides.
Bioconjug. Chem. 27, 3–18 (2016).
35. Koutsopoulos, S. Self‐assembling peptide nanofiber hydrogels in tissue
engineering and regenerative medicine: progress, design guidelines, and
applications. J. Biomed. Mater. Res. A. 104, 1002–1016 (2016).
36. Betush, R. J., Urban, J. M. & Nilsson, B. L. Balancing hydrophobicity and
sequence pattern to influence self‐assembly of amphipathic peptides. Pept. Sci.
110, e23099 (2018).
37. Hamley, I. W. et al. Self-assembly of a model amphiphilic oligopeptide
incorporating an arginine headgroup. Soft Matter 9, 4794–4801 (2013).
38. Gao, J. et al. Controlling self-assembling peptide hydrogel properties through
network topology. Biomacromolecules 18, 826–834 (2017).
39. Tripathi, J. K. et al. Variants of self-assembling peptide, KLD-12 that show
both rapid fracture healing and antimicrobial properties. Biomaterials 56,
92–103 (2015).
40. Sun, J. et al. Biocompatibility of KLD-12 peptide hydrogel as a scaffold in
tissue engineering of intervertebral discs in rabbits. J. Huazhong Univ. Sci.
Technol. [Med. Sci.] 30, 173–177 (2010).
41. Kisiday, J. et al. Self-assembling peptide hydrogel fosters chondrocyte
extracellular matrix production and cell division: implications for cartilage
tissue repair. Proc. Natl Acad. Sci. USA 99, 9996–10001 (2002).
42. Tabatabaei Ghomi, H., Topp, E. M. & Lill, M. A. Fibpredictor: a
computational method for rapid prediction of amyloid fibril structures. J. Mol.
Model. 22, 206 (2016).
43. Zhang, S., Zhao, X. & Spirio, L. In Encyclopedia of Biomedical Polymers and
Polymeric Biomaterials Vol. 11 (ed. Mishra, M.K.) 15 (CRC Press, Boca Raton,
2015).
44. Roeters, S. J. et al. Evidence for intramolecular antiparallel beta-sheet structure
in alpha-synuclein fibrils from a combination of two-dimensional infrared
spectroscopy and atomic force microscopy. Sci. Rep. 7, 41051 (2017).
45. Bulheller, B. M. & Hirst, J. D. DichroCalc—circular and linear dichroism
online. Bioinformatics 25, 539–540 (2009).
46. Khakshoor, O., Demeler, B. & Nowick, J. S. Macrocyclic β-sheet peptides that
mimic protein quaternary structure through intermolecular β-sheet
interactions. J. Am. Chem. Soc. 129, 5558–5569 (2007).
47. Montenegro, J., Ghadiri, M. R. & Granja, J. R. Ion channel models based on
self-assembling cyclic peptide nanotubes. ACC Chem. Res. 46, 2955–2965
(2013).
48. Dinerman, J. L. et al. Increased neutrophil elastase release in unstable angina
pectoris and acute myocardial infarction. J. Am. Coll. Cardiol. 15, 1559–1563
(1990).
49. van den Burg, B. & Eijsink, V. In Handbook of Proteolytic Enzymes (ed.
Salvesen, G.) 540–553 (Academic Press, London, Boston, 2013).
50. Clark, R. J. et al. Engineering stable peptide toxins by means of backbone
cyclization: stabilization of the α-conotoxin MII. Proc. Natl Acad. Sci. USA
102, 13767–13772 (2005).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09587-y ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1735 | https://doi.org/10.1038/s41467-019-09587-y | www.nature.com/naturecommunications 13
51. Chen, Y. et al. Stabilization of peptides against proteolysis through disulfide-
bridged conjugation with synthetic aromatics. Org. Biomol. Chem. 15,
1921–1929 (2017).
52. Tian, Y. F., Hudalla, G. A., Han, H. & Collier, J. H. Controllably degradable β-
sheet nanofibers and gels from self-assembling depsipeptides. Biomater. Sci. 1,
1037–1045 (2013).
53. van den Burg, B. & Eijsink, V. In Handbook of Proteolytic Enzymes Third edn
(eds. Rawlings, N. D. & Salvesen, G.) 540–553 (Academic Press, London,
Boston, 2013).
54. Habibi, N., Kamaly, N., Memic, A. & Shafiee, H. Self-assembled peptide-based
nanostructures: Smart nanomaterials toward targeted drug delivery. Nano
Today 11, 41–60 (2016).
55. Grover, G. N., Braden, R. L. & Christman, K. L. Oxime cross-linked injectable
hydrogels for catheter delivery. Adv. Mater. 25, 2937–2942 (2013).
56. Seif-Naraghi, S. B. et al. Safety and efficacy of an injectable extracellular matrix
hydrogel for treating myocardial infarction. Sci. Transl. Med. 5, 173ra125
(2013).
57. Horton, S. & Augustin, S. In Haemostasis—Methods and Protocols Vol. 992
(ed. Paul Monagle) 155–167 (Humana Press, Springer Science, 2013).
58. Autian, J. In Polymers in Medicine and Surgery. Polymer Science and
Technology Vol. 8 (eds. Kronenthal, R. L., Oser, Z. & Martin, E.) 181–203
(Springer, Boston, 1975).
59. Hee, K. S. et al. Self-assembling peptide nanofibers coupled with neuropeptide
substance P for bone tissue engineering. Tissue Eng. Part A 21, 1237–1246
(2015).
60. Zhu, J. & Marchant, R. E. Design properties of hydrogel tissue-engineering
scaffolds. Expert Rev. Med. Devices 8, 607–626 (2011).
61. Wang, R. M. & Christman, K. L. Decellularized myocardial matrix hydrogels:
in basic research and preclinical studies. Adv. Drug Del. Rev. 96, 77–82
(2016).
62. Gawaz, M. Role of platelets in coronary thrombosis and reperfusion of
ischemic myocardium. Cardiovasc. Res. 61, 498–511 (2004).
63. Roberts, D. E., McNicol, A. & Bose, R. Mechanism of collagen activation in
human platelets. J. Biol. Chem. 279, 19421–19430 (2004).
64. Kim, S. J. et al. Therapeutic effects of neuropeptide substance P coupled with
self-assembled peptide nanofibers on the progression of osteoarthritis in a rat
model. Biomaterials 74, 119–130 (2016).
65. Lu, J. et al. A neurotrophic peptide-functionalized self-assembling peptide
nanofiber hydrogel enhances rat sciatic nerve regeneration. Nano Res. 11,
4599–4613 (2018).
66. Zhang, N., Luo, Y., He, L., Zhou, L. & Wu, W. A self-assembly peptide
nanofibrous scaffold reduces inflammatory response and promotes functional
recovery in a mouse model of intracerebral hemorrhage. Nanomedicine 12,
1205–1217 (2016).
67. Ghomi, H. T., Thompson, J. J. & Lill, M. A. Are distance-dependent statistical
potentials considering three interacting bodies superior to two-body statistical
potentials for protein structure prediction? J. Bioinform. Comput. Biol. 12,
1450022 (2014).
68. Zhou, H. & Skolnick, J. GOAP: a generalized orientation-dependent, all-atom
statistical potential for protein structure prediction. Biophys. J. 101, 2043–2052
(2011).
69. Johnson, T. D. et al. Human versus porcine tissue sourcing for an injectable
myocardial matrix hydrogel. Biomater. Sci. 2014, 60283D (2014).
Acknowledgements
The authors would like to thank G. Policastro, J. Ungerleider, A. Luthi, and M. Spang for
assistance with animal studies, R. Wang and M. Touve for assistance with microscopy,
and N. Ng and J. Madan for aid with cryosectioning. Thanks to the Molinski Lab at UC
San Diego for the use of their CD spectrometer. Thanks to the Ameer Lab at North-
western University for the use of their Hemochron instrument, and Dr. Joost Sluijter at
the University Medical Center Utrecht for providing CPCs. The authors are also grateful
for the support of an NIH Director’s Transformative Research Award (R01HL117326),
part of the NIH Common Fund, the NHLBI (R01HL139001), and an AFORS MURI
(FA9550-16-1-0150). A.S.C. would like to thank the NSF for a Graduate Research Fel-
lowship (DGE-1144086).
Author contributions
A.S.C., N.C.G., and K.L.C. designed the research and analyzed the data. A.S.C. performed
synthetic, computational, biochemical, and animal experiments, and drafted the paper. R.
L.B. and C.L. performed direct intramyocardial injections and myocardial infarction
surgeries, respectively. R.G. performed cell viability assays and toxicity staining. N.C.G.
and K.L.C. provided financial support. K.L.C. and N.C.G. directed the research. All
authors edited the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09587-y.
Competing interests: K.L.C. is co-founder, board member, consultant, and holds equity
interest in Ventrix, Inc. The other authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Ke Cheng and the
other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© This is a U.S. government work and not under copyright protection in the U.S.; foreign
copyright protection may apply 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09587-y
14 NATURE COMMUNICATIONS |         (2019) 10:1735 | https://doi.org/10.1038/s41467-019-09587-y | www.nature.com/naturecommunications
